{Reference Type}: Journal Article
{Title}: USP5 negatively regulates the activation of NLRP3 inflammasomes and participates in the pathological and physiological processes of Sjogren's syndrome.
{Author}: He J;Chen Y;Xu M;Wu S;
{Journal}: Int Immunopharmacol
{Volume}: 135
{Issue}: 0
{Year}: 2024 Jun 30
{Factor}: 5.714
{DOI}: 10.1016/j.intimp.2024.112274
{Abstract}: <B>OBJECTIVE: </B>The current treatment and mechanism of Sjogren's syndrome (SS) are unclear. The purpose of the present study was to potential molecular mechanisms of SS.<BR><B>METHODS: </B>Immunohistochemical and immunofluorescence techniques reveal the targets and therapeutic approaches of SS.<BR><B>RESULTS: </B>We found through molecular biology techniques such as immunoblotting and immunoprecipitation that USP5 is a novel regulator of NLRP3 involvement in the pathological process of SS. USP5 was significantly downregulated in submandibular gland tissue of SS. Meanwhile, it was found that USP5 is a negative regulator of NLRP3 via ubiquitination NLRP3. In addition, SalvianolicacidB (SaB), a natural USP5 agonist, can alleviate ss by regulating the USP5/NLRP3 signaling pathway.<BR><B>CONCLUSIONS: </B>Therefore, this study provides a new mechanism for SS and also provides new therapeutic targets for treating SS.